We studied positivity for anti-cardiolipin antibody, disease activity when compared with changes in the ACA-negative patients ( p<0.05 in all cases). There intraglomerular capillary thrombi on renal biopsy, and the progression of renal disease in 51 patients was no significant difference when patients were separated according to the presence or absence of (10 male and 41 female), mean age 37 years (range 17-65 years), with a diagnosis of systemic lupus thrombi. Renal function at presentation was worse in patients with intracapillary thrombi and ACA erythematosis and clinically evident nephritis confirmed by renal biopsy. Serum creatinine, serum positivity (p=0.085 and p=0.042, respectively). All patients progressed, but only those with indicators of disease activity and biopsies were analysed in subgroups according to thrombi and intracapillary thrombi or anti-cardiolipin antibody positivity had a significant deterioration in renal anticardiolipin status. End-points were death or chronic dialysis requirement and survival. Degree function. Twenty-one thrombotic episodes occurred in 14 patients, of whom 13 were ACA-positive. Antiof sclerosis, crescent formation and necrosed glomeruli were all greater in those specimens positive cardiolipin antibody is a strong predictor of the presence of intraglomerular thrombi in SLE patients for thrombi and in those specimens of patients who were serum ACA-positive, suggesting a relationship with renal involvement. The presence of thrombi and/or anticardiolipin antibodies indicate a worse to disease activity/severity at presentation. The increase in serum anti-DNA antibodies and ANA long-term renal outcome. Anti-cardiolipin antibody positivity is a strong predictor of systemic vascular and the reduction in C3 and C4 were significant in ACA-positive patients, with a strong relationship to thrombotic complications.
Introduction
Antiphospholipid antibodies (aPL), namely the lupus high titres of aPL antibodies, b 2 -GP-I and activation of endothelium or platelets, are now suspected to anticoagulant (LAC) and the anticardiolipin antibodies (ACA) are a group of antibodies directed against encompass the antiphospholipid syndrome (APA). It seems likely that binding of aPL antibodies on negatively-charged phospholipid antigens (phosphatidylserine), on endothelial cell membranes and plateendothelial cells is mediated through the cofactor b 2 -GP-I.4,5 The target antigen for aPL antibodies lets. Previously these antibodies were thought to be directed towards portions of the prothrombin activcould be a complex of b 2 -GP-I and anionic phospholipids. This increasing constellation of antibodies and ator complex, specifically recognizing epitopes on anionic phospholipids and a complex of lipid-bound cofactors has been eloquently summarized by Alarcon-Segovia et al. and others, who have labelled human prothrombin.1,2 More recently this theory has been surpassed by the identification of beta-2-glycoit the antiphospholipid/cofactor syndromes.6,7
The true significance of these antibodies in terms protein-I (b 2 -GP-I).3,4 Several components including of clinical implications and pathogenesis is still controversial. Many studies have confirmed that patients positive for ACA are at risk of repeated episodes of thrombosis, fetal loss and thrombocytopenia. Antiphospholipid antibodies were first identified in patients with systemic lupus erythematosis (SLE) and subsequently in other autoimmune disorders,8-10 but can be found in isolation (the primary antiphospholipid syndrome).11 Antiphospholipid antibodies occur in up to 60% of patients with SLE and may be of pathogenic significance in lupus nephritis. The presence of intraglomerular capillary thrombosis has also been described in SLE nephritis. Intraglomerular capillary thrombi in the renal microcirculation12,13 have been associated with aPL antibodies in lupus patients14 in some series while not in others. 15 However controversy still remains as to their significance in the progression of renal disease and glomerulosclerosis. 16 We therefore carried out a correlation between positivity for ACA and the presence of intraglomerular capillary thrombi on renal biopsy and the progression of renal disease in lupus antiphospholipid antibodies were detected using the nephritis.
Cambridge Life Science ELISA kit (Anti-CL IgM SELISA S4696) for both IgG and IgM subfractions.17 IgA levels were not recorded. A positive ACA (IgM or IgG) above the normal range for our laboratory Methods on any occasion during presentation or follow-up Fifty-one patients (10 male and 41 female), presenting was considered as significant. Positivity for ACA within a 15-year period satisfied the criteria of the remained a consistent finding during follow-up. American Rheumatism Association for the diagnosis Serum markers of disease activity, including antinucof SLE, and had clinically evident nephritis, conlear antibody (ANA) double-stranded DNA antibodies firmed by at least one renal biopsy. The mean age and complement levels (C3 and C4) were measured at the time of renal biopsy was 37 years (range using standard laboratory techniques. We reviewed 17-65 years) and the mean duration of follow-up episodes of systemic thrombosis. was 41 months (range 4-182 months) with a total Plasma creatinine was used as a measure of renal of 1190 patient-months elapsing by the end of the function, with levels of <130 mmol/l (1.4 mg/dl) follow-up period.
being considered as normal. Renal function was A single pathologist who had no prior knowledge compared at the time of biopsy and at the end of of serum immunological or aPL antibody status follow-up. Doubling of serum creatinine (even within examined 56 renal biopsies. Special stains included the normal range) was considered as a significant periodic acid Schiff, the Martius Scarlet Blue (MSB) deterioration in renal reserve. stain for fibrin and silver methenamine preparations.
All patients underwent treatment as deemed necesImmunofluorescence for immunoglobulins and comsary to potentially conserve renal function and proplement was also performed. Renal histology was duce remission from disease activity. This included graded according to the WHO I-V classification of steroids, both oral and intravenous, cyclophosphamseverity for SLE. Numbers of crescents, necrosed and ide pulse therapy, maintenance azathioprine therapy; sclerosed glomeruli were noted. Intraglomerular cyclosporin in three patients, and in four patients, capillary thrombi were identified on light microscopy the use of plasma exchange during episodes of (see Figure 1) . Basic routine clotting studies, the severe relapse. In those patients with episodes of kaolin clotting time (KCCT) and the dilute Russell systemic thrombosis anticoagulant therapy was used viper venom test (DRVVT) were used to identify (warfarin). patients with the lupus anticoagulant. Prolongation of the activated partial thromboplastin time (APPT),
Statistics
KCCT and DRVVT and failure of correction by the addition of normal plasma were considered diaBoth parametric and non-parametric analysis was performed. Correlations between the presence of gnostic of lupus anticoagulant. The presence of of variance (ANOVA). A p value <0.05 was considered statistically significant. capillary thrombus status (Table 3 ). The percentage of glomeruli with sclerosis, cellular crescents or necrosis was higher in thrombi-positive and ACA-
Results
positive cases ( Figure 2 ). The presence of thrombi in A total of 55 biopsies produced sufficient samples the absence of ACA was associated with sclerosis for analysis. The distribution of WHO categories is whereas crescent formation was more common in given in Table 1 . Type IV lupus nephritis was the the ACA-positive patients with no thrombi (Figure 3 ). most common form of nephropathy.
Renal function at presentation was worse in During the follow-up period, two patients became patients with intracapillary thrombi and ACA positivdialysis-dependent, two were transplanted after a ity (p=0.085 and p=0.042, respectively). All period of dialysis dependence, a further seven died, patients progressed, but a significant deterioration in of whom four had been haemodialysis-dependent, renal function was only observed in those with and 14 others suffered systemic thrombotic events.
intracapillary thrombi or ACA positivity (Figures 4 In another seven patients, there was a significant and 5). deterioration in renal function. Three others required However when renal progression was analysed a short period on haemodialysis. Seven patients were according to reciprocal creatinine plots ( Figure 6 ) lost to follow-up/care transferred and were therefore the progression of patients with intracapillary thrombi censored at their most recent follow-up.
was confirmed, whereas there was no demonstrable A total of 930 glomeruli (median 17, range 1-60) deterioration in ACA-positive compared with ACAwere studied for the presence of intraglomerular negative patients. capillary thrombi. Of these there were 159 necrosed, Presence of both intraglomerular thrombi and a 179 sclerosed and 172 glomeruli with crescents. A positive serum ACA in comparison to their absence total of 28 biopsies had intraglomerular thrombi. Of was associated with worse renal function at presentathese the ACA status was unknown in five, positive tion and at the end of follow-up (p=0.03 and p= in 17 and negative in six. There were a total of 27 0.028, respectively) ( Figure 7 ). Those patients positive biopsies with no intraglomerular capillary thrombi.
for both intraglomerular thrombi and ACA demonSeven were ACA-positive while the other 20 were strated a significant deterioration in renal function at negative for ACA. The correlation between the presthe end of the follow-up period in comparison with ence of intraglomerular thrombi and anticardiolipin that at the time of renal biopsy. antibodies was significant (Table 2) .
Survival analysis, using Kaplan-Myer plots with There was a significant association between end-points as death or dialysis, produced a diverdisease activity markers and ACA status but not intragence in survival at 2 years which failed to reach significance when separated according to either ACA (Figures 8 and 9 ). thrombotic episodes (48% of all thrombotic events). 8/76 patients with renal lupus and systemic throm-71% of the ACA-positive SLE patients had glomerular capillary thrombi on biopsy, as previously shown bosis. Unfortunately Miranda et al. 15 did not examine the occurrence of systemic thrombotic events in their by others12,13 compared with 23% of ACA-negative patients. The absence of demonstrable thrombi in large series. In our series, 54% of ACA-positive patients experienced at least one such episode. This the remainder may be attributable to the timing of the biopsy and/or biopsy sampling errors. Glomerular high incidence suggests a pathogenic role for these autoantibodies in the development of thrombi. In the thrombi may also occur in the absence of SLE and thus may be directly related to the presence of earlier series, the low incidence may be related to a failure in clinical detection. Antiphospholipid anticirculating aPL antibodies.31 Intraglomerular capillary thrombi were also associated with glomerulobodies may cause end vascular thrombosis in the form of intravascular coagulation with thrombosis of sclerosis, as previously shown by others.12 This may be due to progressive loss of glomerular function interlobular arteries, arterioles, glomerular capillaries, glomerular subendothelial deposits of granular secondary to the obstruction of the capillaries followed by collapse of affected tufts with subsequent material and glomerular basement membrane reduplication. 30 sclerosis. Viard and colleagues found that 36% of their In keeping with this, we have demonstrated that lupus patients had b 2 -GP-I antibodies; in these and serum markers of disease activity, as well as pathological markers of activity such as crescents. patients there was a strong association with thrombosis,32 and this association has been verified by Our data do not of course prove that the association is causal. However, the lupus anticoagulant is known others.33,34 However, multivariate analysis has shown that aPL antibodies are the strongest risk factor for to impair prostacyclin production, inhibit protein activation by endothelial cells, increase platelet thrombosis, with the presence of b 2 -GP-I having no added significance.35 The picture remains confusing production of thromboxane A2 and increase procoagulant activity, and may therefore cause glomerand complex. As yet, with the rapidly increasing number of described antigens the area remains ular injury.37-40 Since immunosuppressive therapy inhibits the synthesis of antiphospholipid antibodundefined. Possibly aPL antibodies and b 2 -GP-I are distinct entities.36 In our study, b 2 -GP-I antibodies ies,41 this may be another mechanism through which this therapy is effective. confirmed the association of glomerular thrombi with disease in general, may account for any apparent effect of ACA. disease severity, activity of nephritis and also to glomerulosclerosis. They failed to find any relationPatients with both ACA and intraglomerular thrombi had worse renal function at presentation ship with aPL antibodies;15 however, only nine of their patients were positive for aPL antibodies.
than those without either feature alone. This could be due to a longer period of disease activity and/or The presence of thrombi was associated with a worse outcome in our series despite aggressive the treatment regimen used prior to renal biopsy. However, only those patients with both charactertreatment. Further, patients who were positive for both thrombi and ACA had more active SLE and istics demonstrated a significant increase in serum creatinine during the study period, suggesting a more active nephritis. The independent association between crescents and ACA suggests that both are possible synergistic effect of ACA and intraglomerular thrombi. Clarification of this remains difficult, as it immune-mediated, and that ACA positivity is strongly associated with disease activity. Since ACA appears is dependent on when patients were first identified with SLE and renal involvement, and when approto be related to serological markers of disease activity, perhaps the other markers, or more active priate treatment was first instigated. Therefore, the One can postulate that the development of intra- aggressive deterioration in glomerular function. 10. Hughes GR, Harris NM, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13:486-9.
